Premium
Vincristine therapy of lymphomas and chronic lymphocytic leukemia
Author(s) -
Desai Dinesh V.,
Ezdinli Ediz Z.,
Stutzman Leon
Publication year - 1970
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/1097-0142(197008)26:2<352::aid-cncr2820260217>3.0.co;2-8
Subject(s) - medicine , vincristine , chronic lymphocytic leukemia , reticulum cell sarcoma , lymphoma , leukemia , chemotherapy , disease , sarcoma , gastroenterology , oncology , pathology , cyclophosphamide
The results of vincristine therapy in 103 patients with lymphoma and chronic lymphocytic leukemia were evaluated. Seventy‐six per cent of the patients with reticulum cell sarcoma and 62% of those with Hodgkin's disease responded, while the drug was of little benefit in patients with lymphosarcoma and of no value in chronic lymphocytic leukemia. Complete or marked responses were seen in 52% of patients with reticulum cell sarcoma and 20% of patients with Hodgkin's disease. Unmaintained remission was short, lasting a median of 4 weeks. Attempts to prolong the remissions with maintenance vincristine therapy were unsuccessful. No serious neurotoxicity was seen in any of the patients receiving a total dose of less than 7 mg. An unequivocal therapeutic response was evident in all patients before the third dose. If no antitumor effect is observed after two doses, further administration is not indicated.